[go: up one dir, main page]

MX2009012570A - Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida. - Google Patents

Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.

Info

Publication number
MX2009012570A
MX2009012570A MX2009012570A MX2009012570A MX2009012570A MX 2009012570 A MX2009012570 A MX 2009012570A MX 2009012570 A MX2009012570 A MX 2009012570A MX 2009012570 A MX2009012570 A MX 2009012570A MX 2009012570 A MX2009012570 A MX 2009012570A
Authority
MX
Mexico
Prior art keywords
muscle relaxant
providing
botulinum toxin
basis
temperature
Prior art date
Application number
MX2009012570A
Other languages
English (en)
Inventor
Matthias Marx
Swen Grein
Gerd J Mander
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2009012570A publication Critical patent/MX2009012570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un proceso para proporcionar un relajante muscular que es estable a temperaturas superiores a 20ºC, en donde el relajante muscular es una coniposición sólida seca que comprende el componente neurotáxico de la toxina botulínica libre de proteínas complejas.
MX2009012570A 2007-06-01 2008-05-28 Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida. MX2009012570A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
PCT/EP2008/004253 WO2008145358A1 (en) 2007-06-01 2008-05-28 Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form

Publications (1)

Publication Number Publication Date
MX2009012570A true MX2009012570A (es) 2010-03-15

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009012990A MX2009012990A (es) 2007-06-01 2008-05-28 Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.
MX2009012570A MX2009012570A (es) 2007-06-01 2008-05-28 Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009012990A MX2009012990A (es) 2007-06-01 2008-05-28 Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica.

Country Status (15)

Country Link
US (2) US20090028906A1 (es)
EP (2) EP2170375A1 (es)
JP (2) JP2010528999A (es)
KR (2) KR20100020972A (es)
CN (2) CN101720331A (es)
AR (2) AR066783A1 (es)
AU (2) AU2008256419A1 (es)
BR (2) BRPI0812245A2 (es)
CA (2) CA2686637A1 (es)
IL (2) IL202130A0 (es)
MX (2) MX2009012990A (es)
RU (1) RU2009149604A (es)
TW (2) TW200914039A (es)
WO (2) WO2008145359A1 (es)
ZA (2) ZA200907875B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
SMT201800215T1 (it) 2008-12-31 2018-05-02 Revance Therapeutics Inc Formulazioni iniettabili di tossina botulinica domanda di brevetto correlata
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
MX340772B (es) * 2009-02-19 2016-07-26 Merz Pharma Gmbh & Co Kgaa Medios y metodos para fabricar neurotoxina altamente pura.
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US8663942B2 (en) * 2009-04-27 2014-03-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
KR101975051B1 (ko) * 2009-06-25 2019-05-03 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
PT2490986T (pt) * 2009-10-21 2018-11-13 Revance Therapeutics Inc Métodos e sistemas para purificar neurotoxina botulínica não complexada
KR101395064B1 (ko) * 2011-03-31 2014-05-19 (주)메디톡스 보톨리눔 독소의 동결건조제제
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
WO2016102068A1 (en) 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
US10406290B2 (en) * 2015-02-03 2019-09-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled plastic syringe
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
WO2023186016A1 (zh) * 2022-04-01 2023-10-05 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物、制备方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
AU2003231878A1 (en) * 2002-05-31 2003-12-19 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
CN101005853B (zh) * 2004-07-26 2011-05-04 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2006133818A1 (de) 2005-06-17 2006-12-21 Merz Pharma Gmbh & Co. Kgaa Vorrichtung und verfahren zur fermentativen herstellung biologisch wirksamer verbindungen
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
WO2008145358A1 (en) 2008-12-04
CN101720331A (zh) 2010-06-02
JP2010528999A (ja) 2010-08-26
BRPI0812322A2 (pt) 2014-11-25
IL202130A0 (en) 2010-06-16
JP2010529000A (ja) 2010-08-26
TW200914039A (en) 2009-04-01
MX2009012990A (es) 2010-04-01
AU2008256419A1 (en) 2008-12-04
WO2008145359A1 (en) 2008-12-04
AU2008256418A1 (en) 2008-12-04
ZA200907875B (en) 2010-11-24
US20090028906A1 (en) 2009-01-29
EP2170375A1 (en) 2010-04-07
TW200902050A (en) 2009-01-16
KR20100020971A (ko) 2010-02-23
IL202129A0 (en) 2010-06-16
CA2686637A1 (en) 2008-12-04
US20090010965A1 (en) 2009-01-08
EP2164861A1 (en) 2010-03-24
AR066782A1 (es) 2009-09-09
BRPI0812245A2 (pt) 2014-10-21
RU2009149604A (ru) 2011-07-20
CN101687018A (zh) 2010-03-31
ZA200907874B (en) 2011-03-30
KR20100020972A (ko) 2010-02-23
AR066783A1 (es) 2009-09-09
CA2686642A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
MX2009012570A (es) Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida.
EA200970580A1 (ru) Таннат разагилина
ZA200803012B (en) Bitumen composition
TW200719913A (en) Anti-madcam antibody compositions
WO2009149200A3 (en) Compositions and methods comprising variant microbial proteases
WO2008061013A3 (en) Antibody-based diagnostics and therapeutics
MX383346B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
ATE543854T1 (de) Neue polycarbonat-polyorganosiloxan- und/oder polyurethan-polyorganosiloxan-verbindungen
GEP20125652B (en) cMET INHIBITORS
MX2010009456A (es) Composicion detergente que comprende lipasa.
BRPI0922051A2 (pt) Óleos sólidos em pó.
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
ATE493122T1 (de) Casein-komplexe
WO2010015929A3 (en) Uses of mesenchymal stem cells
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
WO2010072420A3 (en) Compositions comprising hemp oil for treating topical diseases, especially hand-foot syndrome
MX2009011648A (es) Componente estructural a base de un material ceramico.
MX2009006615A (es) Proceso para la preparacion y usos de novedosos compuestos de bis(dialquilamida).
MY152388A (en) Composition and method for controlling plant diseases
WO2008056360A3 (en) Chickpea composition
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
WO2008053086A3 (fr) Procede de traitement des ordures menageres
TW200719905A (en) Composition for treating dry eye and related methods of manufacture and methods of use
NO20091386L (no) Fenyloksyanilinderivater
NO20083730L (no) Fremgangsmate for fremstilling av entakapon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal